ProfileGDS5678 / 1439050_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 67% 65% 66% 69% 64% 67% 66% 66% 66% 66% 66% 66% 66% 66% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.0797667
GSM967853U87-EV human glioblastoma xenograft - Control 23.9162765
GSM967854U87-EV human glioblastoma xenograft - Control 34.0239466
GSM967855U87-EV human glioblastoma xenograft - Control 44.3286269
GSM967856U87-EV human glioblastoma xenograft - Control 53.8352564
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.0818567
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.0424366
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.9935666
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.9938566
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.0247266
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.0025966
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.9522266
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.957466
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.0106366